June 2015
Volume 56, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2015
Neurodevelopmental outcomes of preterm infants treated with bevacizumab for severe retinopathy of prematurity
Author Affiliations & Notes
  • Julie Morin
    Universite de Montreal, Montreal, QC, Canada
  • Rosanne Superstein
    Universite de Montreal, Montreal, QC, Canada
    CHU Sainte-Justine, Montreal, QC, Canada
  • Thuy Mai Luu
    Universite de Montreal, Montreal, QC, Canada
    CHU Sainte-Justine, Montreal, QC, Canada
  • Luis Humberto Ospina
    Universite de Montreal, Montreal, QC, Canada
    CHU Sainte-Justine, Montreal, QC, Canada
  • Francine Lefebvre
    Universite de Montreal, Montreal, QC, Canada
    CHU Sainte-Justine, Montreal, QC, Canada
  • Marie-Noelle Simard
    Universite de Montreal, Montreal, QC, Canada
  • Vibuthi Shah
    University of Toronto, Toronto, ON, Canada
    Mount Sinai Hospital, Toronto, ON, Canada
  • Prakesh S Shah
    University of Toronto, Toronto, ON, Canada
    Mount Sinai Hospital, Toronto, ON, Canada
  • Edmond N Kelly
    University of Toronto, Toronto, ON, Canada
    Mount Sinai Hospital, Toronto, ON, Canada
  • Footnotes
    Commercial Relationships Julie Morin, None; Rosanne Superstein, None; Thuy Mai Luu, None; Luis Ospina, None; Francine Lefebvre, None; Marie-Noelle Simard, None; Vibuthi Shah, None; Prakesh Shah, None; Edmond Kelly, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2015, Vol.56, 4323. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Julie Morin, Rosanne Superstein, Thuy Mai Luu, Luis Humberto Ospina, Francine Lefebvre, Marie-Noelle Simard, Vibuthi Shah, Prakesh S Shah, Edmond N Kelly, ; Neurodevelopmental outcomes of preterm infants treated with bevacizumab for severe retinopathy of prematurity. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):4323.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract
 
Purpose
 

Intravitreal injection of bevacizumab, a vascular endothelial growth factor inhibitor (VEGF), is used to treat retinopathy of prematurity (ROP). As bevacizumab can diffuse into the systemic circulation, potential long-term effect on brain development needs to be documented. The purpose of this study is to compare neurodevelopmental outcomes at 18-22 months of preterm infants treated with bevacizumab vs. laser.

 
Methods
 

Data from the Canadian Neonatal Network and the Canadian Neonatal Follow-Up Network databases were retrospectively reviewed. A total of 114 infants born < 29 weeks GA in 2010-2011 with severe ROP (≥ stage 3 or plus disease) requiring treatment and followed at 18-22 months corrected age were studied. Neurodevelopmental outcome was assessed using the Bayley Scales 3rd edition (BSID-III), reporting scores out of a 100 for 3 categories: cognition, language and motor. Regression analyses were performed.

 
Results
 

Of the 114 infants, 32 were injected with bevacizumab (GA 24.8±1.5 weeks, birth weight 740±160g) and 82 had laser therapy (GA 24.8±1.3 weeks, birth weight 711±132g). Neonatal characteristics differed between the bevacizumab vs. laser therapy groups for male sex (62% vs. 42%), SNAP-II score (24 vs. 18), and late onset sepsis (62% vs. 44%). Bevacizumab treated infants had lower motor scores after adjustment for potential confounders. The injected group had a mean difference (95% CI) of -12.0 (-20.0, -3.9) points at th BSID-III and a mean odds ratio of 3.31 (1.10, 9.96) of presenting a motor delay (composite score < 85) compared to the laser treated infants (table 1).

 
Conclusions
 

Preterm infants treated with bevacizumab had lower motor scores compared to those treated with laser therapy. There was no difference in cognition and language scores. Further investigation on the long-term safety of anti-VEGF treatment for ROP is needed.  

 
Table 1: Comparison of developmental outcomes of infants treated with bevacizumab vs laser (baseline group: laser), after adjustment for gestational age, sex, antenatal steroids, multiple birth, bronchopulmonary dysplasia, late onset sepsis, brain injury (intraventricular hemorrhage, periventricular leukomalacia) and maternal education.
 
Table 1: Comparison of developmental outcomes of infants treated with bevacizumab vs laser (baseline group: laser), after adjustment for gestational age, sex, antenatal steroids, multiple birth, bronchopulmonary dysplasia, late onset sepsis, brain injury (intraventricular hemorrhage, periventricular leukomalacia) and maternal education.

 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×